Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: jargonweary who wrote (992)	5/5/2025 12:33:33 PM
From: Maturin	Read Replies (1) \| Respond to of 1229

Obviously the company was working their response all weekend long given they received communication from the FDA on May 2nd. Notable that the consultant hired by IBRX is quoted in the release with some strong words for the FDA's decision. My two cents: all of this smacks of egos and reputations at this point, which isn't good for patients or shareholders.

To: jargonweary who wrote (992)	5/5/2025 12:38:26 PM
From: galt	3 Recommendations Recommended By bobbseytwins2001 erippetoe urslor Read Replies (1) \| Respond to of 1229

Unfortunately, this could lead to another class action suit. Just saying, but hoping not. Agree that the volume today is suggesting that this might be about something else. Hoping not, but, like Tinfoil, I'm using it to average down. I do not think we're looking at years, but maybe months, to right the ship on other indication trials. Given that Anktiva is already approved for one cancer, and has shown very good early results on others, I'm ok adding more at this point. Having said that, I'm kinda sure that mgmt. screwed up in some way. I'm hoping politics is not a part of this, but in this crazy world, who knows. Let's hope that we hear more, sooner rather than later. Best